#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
CS
proLékaře.cz / Journals / Journal of Czech Physicians / 2020 - 5

A case of severe course of COVID-19 treated with experimental therapy

Czech version

Authors: Milan Zlámal 1;  Katarína Štěchovská 2;  Michal Holub 1
Authors‘ workplace: Klinika infekčních nemocí 1. LF UK a ÚVN Praha 1;  Interní klinika 1. LF UK a ÚVN Praha 2
Published in: Čas. Lék. čes. 2020; 159: 181-184
Category: Case Report

Overview

70-year-old high-risk patient with severe course of COVID-19 hospitalized for progressive dyspnea due to extensive bilateral pneumonia caused by SARS-CoV-2. The patient was treated with hydroxychloroquine and azithromycin from day one of hospital stay. Because of progression on the therapy, the convalescent plasma was administered on day three of hospitalization. The patient subsequently improved and was discharged home on day eleven of the hospital stay.

Risk factors of severe course of the infection, complications and potential therapies of COVID-19 are discussed.

Keywords:

SARS-CoV-2 – COVID-19 – viral pneumonia – hydroxychloroquine – azithromycin – blood plasma

Sources

  1. Cuccinota D, Vanelli M. WHO declares COVID-19 pandemic. Acta Biomed 2020; 91: 157–160.

  2. Li B, Yang J, Zhao F et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol 2020; 109: 531–538.

  3. Zhou F, Yu T, Du R et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054–1062.

  4. Chen T, Wu D, Chen H et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020; 368: m1091.

  5. Kupferschmidt K, Cohen J. Race to find COVID-19 treatments accelerates. Science 2020; 367: 1412–1413.

  6. Gattinoni L, Chiumello D, Rossi S. COVID-19 pneumonia: ARDS or not? Crit Care 2020; 24: 154.

  7. Guan W, Ni Z, Liang W et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382: 1708–1720.

  8. McGonagle D, Sharif K, O’Regan A et al. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev 2020; 102537.

  9. Ranucci M, Ballotta A, Di Dedda U et al. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J Thromb Haemost 2020; 18: 1747–1751.

  10. Blackburn WD Jr, Prupas HM, Silverfield JC et al. Tenidap in rheumatoid arthritis. A 24-week double-blind comparison with hydroxychloroquine-plus-piroxicam, and piroxicam alone. Arthritis Rheum 1995; 38: 1447–1456.

  11. Kümpel P, Holub M, Roháčová H, Plíšek S. Doporučený postup SIL ČLS JEP léčby pacientů s prokázanou infekcí COVID-19. Společnost infekčního lékařství ČLS JEP, 2020. Dostupné na: www.infekce.cz/Covid2019/DP-SIL-covid120520p.pdf

  12. Liu J, Cao R, Xu M et al. Hydroxychloroquine, a less toxic chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 2020; 6: 16.

  13. Gautret P, Lagier JC, Parola P et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020; 56: 105949.

  14. Rosenberg ES, Dufort EM, Udo T et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state. JAMA 2020; 323: 2493–2502.

  15. Gilead Sciences statement on expanding global supply of investigational antiviral remdesivir. Dostupné na: www.gilead.com/news-and-press/company-statements/gilead-sciences-statement-on-remdesivir-global-supply

  16. Duan K, Liu B, Li C et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A 2020; 117: 9490–9496.

  17. Doporučený postup pro použití rekonvalescentní plazmy v léčbě dospělých pacientů s COVID-19. ČSARIM ČLS JEP, STL ČLS JEP, SIL ČLS JEP, Klinická skupina COVID MZ, 30. 4. 2019. Dostupné na: www.infekce.cz/Covid2019/DPtrf-covid050520.pdf

  18. Posuzování způsobilosti k dárcovství krve a krevních složek. Společnost pro transfuzní lékařství ČLS JEP, 2019. Dostupné na: www.transfuznispolecnost.cz/doporucene-postupy/posuzovani-zpusobilosti-k-darcovstvi-krve-a-krevnich-slozek-239

Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management Dental Hygienist
Production and use of convalescent plasma in COVID-19 treatment, taking into account the experience in the Central Millitary Hospital Prague
Úvodem
Role of blood biomarkers in spontaneous intracerebral hemorrhage – a prospectively studied cohort of patients
Psychosomatic and psychosocial aspects of health risks perception rising from living and occupational settings
Gambling products and their risk potential for gambling disorder
New trends in teaching anatomy and our experience with teaching anatomy in Czech during quarantine regarding COVID-19 pandemic
Health care at the St. George Monastery at the Prague Castle in the 17th and 18th century
Custodial, corporal, capital punishment? Death in St. Wenceslas and Pankrac prisons 1827–1926
Zapomenutý gastroenterolog?
Opustila nás prof. Eva Seemanová
Zemřel nestor české ortopedie prof. Oldřich Čech
Article was published in

Journal of Czech Physicians

Issue 5
2020 Issue 5
Download issue PDF
Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#